Cargando…

Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study

Chromium has long been known as an enhancer of insulin action. However, the role of chromium in the development of type 2 diabetes mellitus (T2DM) in humans remains controversial. The current study aimed to examine the associations of plasma chromium levels with T2DM and pre-diabetes mellitus (pre-D...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Sijing, Jin, Xiaoling, Shan, Zhilei, Li, Shuzhen, Yin, Jiawei, Sun, Taoping, Luo, Cheng, Yang, Wei, Yao, Ping, Yu, Kaifeng, Zhang, Yan, Cheng, Qian, Cheng, Jinquan, Bao, Wei, Liu, Liegang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372957/
https://www.ncbi.nlm.nih.gov/pubmed/28304331
http://dx.doi.org/10.3390/nu9030294
_version_ 1782518726676971520
author Chen, Sijing
Jin, Xiaoling
Shan, Zhilei
Li, Shuzhen
Yin, Jiawei
Sun, Taoping
Luo, Cheng
Yang, Wei
Yao, Ping
Yu, Kaifeng
Zhang, Yan
Cheng, Qian
Cheng, Jinquan
Bao, Wei
Liu, Liegang
author_facet Chen, Sijing
Jin, Xiaoling
Shan, Zhilei
Li, Shuzhen
Yin, Jiawei
Sun, Taoping
Luo, Cheng
Yang, Wei
Yao, Ping
Yu, Kaifeng
Zhang, Yan
Cheng, Qian
Cheng, Jinquan
Bao, Wei
Liu, Liegang
author_sort Chen, Sijing
collection PubMed
description Chromium has long been known as an enhancer of insulin action. However, the role of chromium in the development of type 2 diabetes mellitus (T2DM) in humans remains controversial. The current study aimed to examine the associations of plasma chromium levels with T2DM and pre-diabetes mellitus (pre-DM). We conducted a case-control study involving 1471 patients with newly diagnosed T2DM, 682 individuals with newly diagnosed pre-DM, and 2290 individuals with normal glucose tolerance in a Chinese population from 2009 to 2014. Plasma chromium was measured by inductively coupled plasma mass spectrometry. Plasma chromium levels were lower in the T2DM and pre-DM groups than in the control group (median: 3.68 μg/L, 3.61 μg/L, 3.97 μg/L, respectively, p < 0.001). After adjustment for potential confounding factors, the odds ratios (95% confidence interval) for T2DM across increasing quartiles of plasma chromium levels were 1 (referent), 0.67 (0.55–0.83), 0.64 (0.51–0.79), and 0.58 (0.46–0.73), respectively (p for trend <0.001). The corresponding odds ratios (95% confidence interval) for pre-DM were 1 (referent), 0.70 (0.54–0.91), 0.67 (0.52–0.88), and 0.58 (0.43–0.78), respectively (p for trend < 0.001). Our results indicated that plasma chromium concentrations were inversely associated with T2DM and pre-DM in Chinese adults.
format Online
Article
Text
id pubmed-5372957
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53729572017-04-05 Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study Chen, Sijing Jin, Xiaoling Shan, Zhilei Li, Shuzhen Yin, Jiawei Sun, Taoping Luo, Cheng Yang, Wei Yao, Ping Yu, Kaifeng Zhang, Yan Cheng, Qian Cheng, Jinquan Bao, Wei Liu, Liegang Nutrients Article Chromium has long been known as an enhancer of insulin action. However, the role of chromium in the development of type 2 diabetes mellitus (T2DM) in humans remains controversial. The current study aimed to examine the associations of plasma chromium levels with T2DM and pre-diabetes mellitus (pre-DM). We conducted a case-control study involving 1471 patients with newly diagnosed T2DM, 682 individuals with newly diagnosed pre-DM, and 2290 individuals with normal glucose tolerance in a Chinese population from 2009 to 2014. Plasma chromium was measured by inductively coupled plasma mass spectrometry. Plasma chromium levels were lower in the T2DM and pre-DM groups than in the control group (median: 3.68 μg/L, 3.61 μg/L, 3.97 μg/L, respectively, p < 0.001). After adjustment for potential confounding factors, the odds ratios (95% confidence interval) for T2DM across increasing quartiles of plasma chromium levels were 1 (referent), 0.67 (0.55–0.83), 0.64 (0.51–0.79), and 0.58 (0.46–0.73), respectively (p for trend <0.001). The corresponding odds ratios (95% confidence interval) for pre-DM were 1 (referent), 0.70 (0.54–0.91), 0.67 (0.52–0.88), and 0.58 (0.43–0.78), respectively (p for trend < 0.001). Our results indicated that plasma chromium concentrations were inversely associated with T2DM and pre-DM in Chinese adults. MDPI 2017-03-17 /pmc/articles/PMC5372957/ /pubmed/28304331 http://dx.doi.org/10.3390/nu9030294 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Sijing
Jin, Xiaoling
Shan, Zhilei
Li, Shuzhen
Yin, Jiawei
Sun, Taoping
Luo, Cheng
Yang, Wei
Yao, Ping
Yu, Kaifeng
Zhang, Yan
Cheng, Qian
Cheng, Jinquan
Bao, Wei
Liu, Liegang
Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study
title Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study
title_full Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study
title_fullStr Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study
title_full_unstemmed Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study
title_short Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study
title_sort inverse association of plasma chromium levels with newly diagnosed type 2 diabetes: a case-control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372957/
https://www.ncbi.nlm.nih.gov/pubmed/28304331
http://dx.doi.org/10.3390/nu9030294
work_keys_str_mv AT chensijing inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT jinxiaoling inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT shanzhilei inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT lishuzhen inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT yinjiawei inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT suntaoping inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT luocheng inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT yangwei inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT yaoping inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT yukaifeng inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT zhangyan inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT chengqian inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT chengjinquan inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT baowei inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy
AT liuliegang inverseassociationofplasmachromiumlevelswithnewlydiagnosedtype2diabetesacasecontrolstudy